Patents Assigned to Genentech
  • TDO2 and IDO1 inhibitors
    Patent number: 11603373
    Abstract: Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: March 14, 2023
    Assignee: GENENTECH, INC.
    Inventors: Zhonghua Pei, Richard Pastor, Lewis Gazzard, Brendan Parr, Wendy Liu, Rohan Mendonca, Guosheng Wu, Po-wai Yuen
  • PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF
    Publication number: 20230074486
    Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
    Type: Application
    Filed: November 1, 2022
    Publication date: March 9, 2023
    Applicants: Genentech, Inc., Novartis AG
    Inventor: Charles M. WINTER
  • Apolipoprotein L1-Specific Antibodies and Methods of Use
    Publication number: 20230071609
    Abstract: This disclosure provides anti-apolipoprotein L1 (APOL1) antibodies, including anti-APOL1 antibodies that distinguish the GO and G1 forms from the G2 form of APOL1, distinguish APOL1 found on podocytes from that found on HDL particles in serum, and distinguish APOL1 from apolipoproteins L2, L3, L4 and L6 (APOL2, APOL3, APOL4 and APOL6), and methods of using the same.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 9, 2023
    Applicant: Genentech Inc.
    Inventors: Suzanna Jane Scales, Nidhi Gupta, Andrew Scott Peterson
  • HARVEST OPERATIONS FOR RECOMBINANT PROTEINS
    Publication number: 20230069966
    Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
    Type: Application
    Filed: July 13, 2022
    Publication date: March 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
  • Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof
    Patent number: 11597776
    Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: March 7, 2023
    Assignee: Genentech, Inc.
    Inventors: Reed J Harris, Paul A. Motchnick
  • Methods of detecting polyubiquitin using anti-polyubiquitin antibodies
    Patent number: 11597761
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: March 7, 2023
    Assignee: Genentech Inc.
    Inventors: Robert F. Kelley, Vishva Dixit, Marissa L. Matsumoto
  • VISMODEGIB IN COMBINATION WITH A REPLICATION-DEFICIENT TYPE 5 ADENOVIRUS FOR EXPRESSION OF INTERFERON GAMMA FOR THE TREATMENT OF SKIN CANCER
    Publication number: 20230065168
    Abstract: Provided are methods of treating skin cancer in an individual in need thereof by administering to the individual vismodegib and a replication-deficient type 5 adenovirus for expression of interferon gamma.
    Type: Application
    Filed: March 30, 2022
    Publication date: March 2, 2023
    Applicants: ASCEND BIOPHARMACEUTICALS LTD, Genentech, Inc.
    Inventors: Clement Leong, Geoffrey Pietersz, Edward F. McKenna, JR.
  • CONJUGATED CHEMICAL INDUCERS OF DEGRADATION AND METHODS OF USE
    Publication number: 20230067037
    Abstract: The subject matter described herein is directed to antibody-CIDE conjugates (Ab-CIDEs), to pharmaceutical compositions containing them, and to their use in treating diseases and conditions where targeted protein degradation is beneficial.
    Type: Application
    Filed: April 23, 2021
    Publication date: March 2, 2023
    Applicant: Genentech, Inc.
    Inventors: Peter DRAGOVICH, Thomas PILLOW, Robert Anthony BLAKE, Ingrid WERTZ
  • USE OF HUMAN EPIDIDYMIS PROTEIN 4 (HE4) FOR ASSESSING RESPONSIVENESS OF MUC 16-POSITIVE CANCER TREATMENT
    Publication number: 20230064677
    Abstract: The present invention relates to methods and kits or articles of manufacture related thereto that may find use, inter alia, in assessing responsiveness of cancers to MUC16 antagonists by monitoring HE4 expression. In some embodiments, the methods include measuring the level of expression of HE4 in a sample from a subject; comparing the level of expression of HE4 in the sample with the level of expression of HE4 in a sample previously obtained from the subject; and, optionally, administering to the subject a therapeutically effective amount of a MUC16 antagonist.
    Type: Application
    Filed: August 2, 2022
    Publication date: March 2, 2023
    Applicant: Genentech, Inc
    Inventors: Mark LACKNER, Daniel Maslyar, Yulei Wang, Walter Darbonne, Eric Humke
  • Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
    Patent number: 11590128
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 28, 2023
    Assignees: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • Expression of Fc-containing proteins
    Patent number: 11591382
    Abstract: The present invention provides compositions comprising a Fc-containing protein wherein substantially all the Fc domains have a C-terminal lysine. Further provided are host cell for producing said compositions, methods of making said host cells and compositions, and method of use thereof.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: February 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Benjamin Haley, Zhilan Hu, John C. Joly, Amy Y. Shen, Bradley Richard Snedecor
  • Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
    Patent number: 11591345
    Abstract: The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 28, 2023
    Assignee: Genentech, Inc.
    Inventors: Paroma Chakravarty, Chong Han, Sean M. Kelly, Karthik Nagapudi, Scott Savage
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE
    Publication number: 20230054741
    Abstract: The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 23, 2023
    Applicant: Genentech, Inc.
    Inventors: Jason R. Zbieg, Paul Powell Beroza
  • Structures for Reducing Antibody-Lipase Binding
    Publication number: 20230048743
    Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.
    Type: Application
    Filed: July 8, 2022
    Publication date: February 16, 2023
    Applicant: Genentech Inc.
    Inventors: Elizabeth Sara Hecht, Shrenik Chetan Mehta, Wendy Noel Sandoval, Sreedhara Alavattam, Nathaniel Robert Tzizik-Swanson
  • ANTI-PD-L1 ANTIBODIES AND METHODS OF USING THE SAME FOR DETECTION OF PD-L1
    Publication number: 20230052312
    Abstract: The present application relates to anti-PD-L1 antibodies and their use to detect PD-L1 in a sample from a subject. In some embodiments, the subject has been treated with a therapeutic anti-PD-L1 antibody and an anti-PD-L1 described herein does not compete for binding to PD-L1 with the therapeutic anti-PD-L1 antibody. In some embodiments, the anti-PD-L1 antibody is linked to a detectable moiety, such as a fluorophore and the anti-PD-L1 antibody is used to detect PD-L1 in a subject using flow cytometry.
    Type: Application
    Filed: February 16, 2022
    Publication date: February 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Doris KIM, Terence Wong, Anan Chuntharapai, Cherie Louise Green
  • ANTI-C-C MOTIF CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE
    Publication number: 20230049152
    Abstract: The present disclosure provides anti-CCR8 antibodies, and compositions and methods of their preparation and use.
    Type: Application
    Filed: July 13, 2022
    Publication date: February 16, 2023
    Applicant: GENENTECH, INC.
    Inventors: Gautham Gampa, Iraj Hosseini, Mahrukh Huseni, James T. Koerber, Jian Mehr-Dean Payandeh, Sascha Rutz, Yonglian Sun, Cecilia P. C. Chiu, Teresita A. Delfino
  • PERTUZUMAB VARIANTS AND EVALUATION THEREOF
    Publication number: 20230047103
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: June 27, 2022
    Publication date: February 16, 2023
    Applicant: Genentech, Inc.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant
    Patent number: 11576919
    Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: February 14, 2023
    Assignee: Genentech, Inc.
    Inventor: Kui Lin
  • Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
    Patent number: 11576979
    Abstract: The invention relates generally to pyrrolobenzodiazepine monomer and dimer prodrugs having a glutathione-activated disulfide prodrug moiety, a DT-diaphorase-activated quinone prodrug moiety or a reactive oxygen species-activated aryl boronic acid or aryl boronic ester prodrug moiety. The invention further relates to pyrrolobenzodiazepine prodrug dimer-antibody conjugates.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 14, 2023
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Zhonghua Pei, Thomas Pillow, Jack Sadowsky, Vishal Verma, Donglu Zhang
  • COMPOSITIONS AND METHODS OF TREATING LUPUS NEPHRITIS
    Publication number: 20230039927
    Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
    Type: Application
    Filed: August 2, 2022
    Publication date: February 9, 2023
    Applicant: Genentech, Inc.
    Inventor: Matthew Dominic CASCINO